Cargando…
Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.”
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886953/ https://www.ncbi.nlm.nih.gov/pubmed/29274466 http://dx.doi.org/10.1016/j.pvr.2017.12.005 |
| _version_ | 1783312195445063680 |
|---|---|
| author | Ryser, Martin Guignard, Adrienne Berlaimont, Valérie |
| author_facet | Ryser, Martin Guignard, Adrienne Berlaimont, Valérie |
| author_sort | Ryser, Martin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5886953 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58869532018-04-11 Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” Ryser, Martin Guignard, Adrienne Berlaimont, Valérie Papillomavirus Res Article Elsevier 2017-12-20 /pmc/articles/PMC5886953/ /pubmed/29274466 http://dx.doi.org/10.1016/j.pvr.2017.12.005 Text en © 2017 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Article Ryser, Martin Guignard, Adrienne Berlaimont, Valérie Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| title | Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| title_full | Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| title_fullStr | Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| title_full_unstemmed | Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| title_short | Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| title_sort | letter-to-the-editor in response to “tanton c, et al. human papillomavirus (hpv) in young women in britain: population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. papillomavirus res. 2017 jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.” |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886953/ https://www.ncbi.nlm.nih.gov/pubmed/29274466 http://dx.doi.org/10.1016/j.pvr.2017.12.005 |
| work_keys_str_mv | AT rysermartin lettertotheeditorinresponsetotantoncetalhumanpapillomavirushpvinyoungwomeninbritainpopulationbasedevidenceoftheeffectivenessofthebivalentimmunisationprogrammeandburdenofquadrivalentand9valentvaccinetypespapillomavirusres2017jun33641doi101016jpvr201701001 AT guignardadrienne lettertotheeditorinresponsetotantoncetalhumanpapillomavirushpvinyoungwomeninbritainpopulationbasedevidenceoftheeffectivenessofthebivalentimmunisationprogrammeandburdenofquadrivalentand9valentvaccinetypespapillomavirusres2017jun33641doi101016jpvr201701001 AT berlaimontvalerie lettertotheeditorinresponsetotantoncetalhumanpapillomavirushpvinyoungwomeninbritainpopulationbasedevidenceoftheeffectivenessofthebivalentimmunisationprogrammeandburdenofquadrivalentand9valentvaccinetypespapillomavirusres2017jun33641doi101016jpvr201701001 |